ENOV ENOVIS CORPORATION

Enovis™ Introduces STAR® Ankle, now with e+™ Polyethylene for Unmatched Durability

Enovis™ Introduces STAR® Ankle, now with e+™ Polyethylene for Unmatched Durability

Revolutionary Scandinavian Total Ankle Replacement (STAR® Ankle) System Now Includes Vitamin E-Blended Polyethylene Insert

Wilmington, DE, Aug. 19, 2024 (GLOBE NEWSWIRE) --  Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology company, proudly unveils its Scandinavian Total Ankle Replacement (STAR® Ankle), now with new e+™ Polyethylene. Recent U.S. Food and Drug Administration (FDA) approval makes STAR® Ankle the first and only mobile bearing ankle system with e+™ Polyethylene in the United States.1 The implant’s new vitamin E-blended e+™ Polyethylene insert will offer improved durability, stability, and longevity.1

"With e+™ Polyethylene, we uphold our commitment to the advancement of our total ankle portfolio, merging full oxidative resistance with the time-tested design of the STAR® Ankle,” said Gary Justak, President and General Manager of Enovis Foot & Ankle. “Building upon the proven success of the STAR® Ankle epitomizes our culture of advancing foot and ankle solutions and elevating patient treatment options. We don't just set the standard—we redefine it.”

e+™ Polyethylene contains the free radical-neutralizing antioxidant vitamin E; as a result, the material resists oxidation and maintains consistent wear rates and stable mechanical properties over time. In contrast, other highly crosslinked polyethylenes are remelted during manufacturing to neutralize free radicals2, a process that can reduce their mechanical strength by up to 12%.1,3

“After extensive clinical experience with this superior material in knee and shoulder implants, along with years of laboratory testing, I expect improved patient outcomes through increased polyethylene longevity. This builds on the outstanding STAR® Ankle long-term metal-component survival rates seen in multiple clinical studies,” stated Dr. Gregory Lundeen, a foot and ankle orthopedic surgeon at Reno Orthopedic Center.

Combined with the recent release of STAR Patient Specific Instrumentation (PSI), the STAR+ Experience represents Enovis’ commitment to continuous improvement, aimed at enhancing patient satisfaction and outcomes. The integration of e+™ Polyethylene in the STAR® Ankle continues to enhance the remarkable success of this implant, which has been used globally over 40,000 times across its 37-year history.4

For more information about the STAR® Ankle with e+™ Polyethylene and Enovis' innovative foot and ankle solutions, please visit .

Individual results may vary. Neither Enovis™ Corporation nor any of its subsidiaries dispense medical advice. The contents of this release do not constitute medical, legal, or any other type of professional advice. Rather, please consult your healthcare professional for information on the courses of treatment, if any, which may be appropriate for you.

Dr. Gregory Lundeen is a consultant for Enovis™ Corporation.

References

  1. e+ testing data on file. Bench test results not necessarily indicative of clinical performance.
  2. Jennings et al. The influence of femoral condylar lift-off on the wear of artificial knee joints. Proc Inst Mech Eng [H]. 2007 Apr;221(3):305-14.
  3. S.M. Kurtz. “The UHMWPE Handbook: Ultra-high Molecular Weight Polyethylene in Total Joint Replacement”. Elsevier Academic Press, 2009.
  4. Enovis® internal document: Includes world-wide implantations of all generations; newest generation has over 40,000 world-wide from 1998-2022



About Enovis

Enovis™ Corporation (NYSE: ENOV) is an innovation-driven medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the Company’s extensive range of products, services, and integrated technologies fuels active lifestyles in orthopedics and beyond. For more information about Enovis, please visit .

Media Contact

Diana Aldermae

Enovis Foot & Ankle

MK-10554

Attachment



EN
19/08/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ENOVIS CORPORATION

 PRESS RELEASE

Enovis to Participate in Upcoming Investor Conferences

Enovis to Participate in Upcoming Investor Conferences Wilmington, DE, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences: Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13th at 8:30 a.m. Eastern Time.Wells Fargo Healthcare Conference on Wednesday, September 3rd at 2:15 p.m. Eastern Time.Baird 2025 Global Healthcare Conference on Wednesday, September 10th at 3:10 p.m. Eastern Time. A link to the l...

 PRESS RELEASE

Enovis Announces Second Quarter 2025 Results

Enovis Announces Second Quarter 2025 Results Continued commercial momentum with second-quarter sales growth of 7% on a reported basisSecond-quarter Reconstructive sales grew 11% year-over-year on a reported basis  Wilmington, DE, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the second quarter ended July 4, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. Second Quarter 2...

 PRESS RELEASE

Enovis to Host Second Quarter 2025 Results Conference Call on August 7...

Enovis to Host Second Quarter 2025 Results Conference Call on August 7th Wilmington, DE, July 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its second quarter 2025 financial results on Thursday, August 7th, 2025, at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call, as well as a webcast, can be accessed from the "Investors" section of Enovis' website at . Conference C...

 PRESS RELEASE

Enovis to Participate in Upcoming Investor Conferences

Enovis to Participate in Upcoming Investor Conferences Wilmington, DE, June 06, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences: Goldman Sachs 46th Annual Global Healthcare Conference: Ben Berry, Chief Financial Officer, will participate in a fireside chat on Tuesday, June 10th at 2:00 p.m. Eastern Time.Citizens Medical Devices and Healthcare Services Forum: Ben Berry, Chief Financial Officer, will participate in investor meet...

 PRESS RELEASE

Enovis Announces First Quarter 2025 Results

Enovis Announces First Quarter 2025 Results Continued commercial momentum with first-quarter sales growth of 8% on a reported basis and strong adjusted EBITDA margin expansion First-quarter Reconstructive sales grew 11% year-over-year on a reported basis Appointed Damien McDonald as CEO, effective May 12th, 2025 Wilmington, DE, May 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the first quarter ended April 4, 2025. The Company will host an ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch